{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:55:36Z","timestamp":1770069336812,"version":"3.49.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This article provides information and a commentary on landmark trials presented at the American College of Cardiology meeting held in March 2005, relevant to the pathophysiology, prevention and treatment of heart failure. All reports should be considered as preliminary data, as analyses may change in the final publication. CARE-HF showed that Cardiac Re-synchronisation Therapy, administered in addition to expert pharmacological management, reduced all cause mortality and CV hospitalisation in patients with moderate or severe heart failure and cardiac dyssynchrony. The Women\u2019s Health Study showed no benefit of vitamin E supplementation or aspirin in the primary prevention of CV disease. The TNT study showed that reducing LDL cholesterol to levels lower than currently recommended, produced a 22% reduction in the incidence of major cardiovascular events. In COMPASS, an implantable device that continuously monitors intra-cardiac pressures was shown to be safe and to improve care in patients with chronic heart failure. Tezosentan failed to show benefit in patients with acute heart failure in the VERITAS study. The CANPAP study failed to show a benefit of continuous positive airway pressure on mortality and heart transplantation in heart failure patients with central sleep apnoea. EECP therapy improved exercise capacity but had no effect on peak VO2 in heart failure patients in the PEECH study. In the PREMIER study the matrix metalloproteinase inhibitor PG-116800 failed to prevent LV remodelling following myocardial infarction.<\/jats:p>","DOI":"10.1016\/j.ejheart.2005.04.002","type":"journal-article","created":{"date-parts":[[2005,5,6]],"date-time":"2005-05-06T19:09:41Z","timestamp":1115406581000},"page":"931-936","source":"Crossref","is-referenced-by-count":41,"title":["Clinical Trials Update from the American College of Cardiology Meeting: CARE-HF and the Remission of Heart Failure, Women\u2019s Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER"],"prefix":"10.1093","volume":"7","author":[{"given":"John G.F.","family":"Cleland","sequence":"first","affiliation":[{"name":"Department of Cardiology, University of Hull, Castle Hill Hospital , Cottingham, Kingston-upon-Hull, HU15 5JQ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison P.","family":"Coletta","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Hull, Castle Hill Hospital , Cottingham, Kingston-upon-Hull, HU15 5JQ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Freemantle","sequence":"additional","affiliation":[{"name":"Department of Primary Care and General Practice, University of Birmingham , Edgbaston, Birmingham, B15 2TT ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Periaswamy","family":"Velavan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Hull, Castle Hill Hospital , Cottingham, Kingston-upon-Hull, HU15 5JQ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lwin","family":"Tin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Hull, Castle Hill Hospital , Cottingham, Kingston-upon-Hull, HU15 5JQ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew L.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Hull, Castle Hill Hospital , Cottingham, Kingston-upon-Hull, HU15 5JQ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,8,7]]},"reference":[{"key":"2026020203555857000_ejhf2005-04-002-bib-0001","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.ejheart.2004.07.007","article-title":"Clinical trials update from the European Society of Cardiology heart failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy","volume":"6","author":"Coletta","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"2026020203555857000_ejhf2005-04-002-bib-0002","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1388-9842(01)00176-3","article-title":"Design and methodology of the CARE-HF trial. A randomised trial of cardiac resynchronisation in patients with heart failure and ventricular dyssynchrony","volume":"3","author":"Cleland","year":"2001","journal-title":"Eur J Heart Fail"},{"key":"2026020203555857000_ejhf2005-04-002-bib-0003","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ejheart.2005.01.010","article-title":"Baseline characteristics of patients recruited into the CARE-HF study","volume":"7","author":"Cleland","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"2026020203555857000_ejhf2005-04-002-bib-0004","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronisation on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N Engl J Med"},{"key":"2026020203555857000_ejhf2005-04-002-bib-0005","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa032423","article-title":"Cardiac resynchronisation therapy with or without an implantable defibrillator in advanced chronic heart failure","volume":"350","author":"Bristow","year":"2004","journal-title":"N Engl J Med"},{"key":"2026020203555857000_ejhf2005-04-002-bib-0006","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1001\/jama.293.11.1338","article-title":"Effects of long term vitamin E supplementation on cardiovascular events and cancer: a randomised controlled trial","volume":"293","author":"Lonn","year":"2005","journal-title":"JAMA"},{"key":"2026020203555857000_ejhf2005-04-002-bib-0007","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1001\/jama.293.11.1387","article-title":"Is there any hope for vitamin E=","volume":"293","author":"Brown","year":"2005","journal-title":"JAMA"},{"key":"2026020203555857000_ejhf2005-04-002-bib-0008","volume-title":"Vitamin E increases all-cause mortality","author":"Wood"},{"key":"2026020203555857000_ejhf2005-04-002-bib-0009","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomised trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"2026020203555857000_ejhf2005-04-002-bib-0010","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1053\/pcad.2002.31597","article-title":"Is aspirin the \u201cweakest link\u201d in cardiovascular prophylaxis= The surprising lack of evidence supporting the use of aspirin for cardiovascular disease","volume":"44","author":"Cleland","year":"2002","journal-title":"Prog Cardiovasc Dis"},{"key":"2026020203555857000_ejhf2005-04-002-bib-0011","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"2026020203555857000_ejhf2005-04-002-bib-0012","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"2026020203555857000_ejhf2005-04-002-bib-0013","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.jacc.2003.07.016","article-title":"The relationship between cholesterol and survival in patients with chronic heart failure","volume":"42","author":"Rauchhaus","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026020203555857000_ejhf2005-04-002-bib-0014","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jacc.2003.07.049","article-title":"Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure","volume":"43","author":"Horwich","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2026020203555857000_ejhf2005-04-002-bib-0015","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.amjcard.2004.01.039","article-title":"Statin therapy is associated with lower mortality among patients with severe heart failure","volume":"93","author":"Mozaffarian","year":"2004","journal-title":"Am J Cardiol"},{"key":"2026020203555857000_ejhf2005-04-002-bib-0016","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ejheart.2004.03.001","article-title":"Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure","volume":"6","author":"Tavazzi","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"2026020203555857000_ejhf2005-04-002-bib-0017","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin converting enzyme inhibitor lisinopril on morbidity and mortality in chronic heart failure","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"2026020203555857000_ejhf2005-04-002-bib-0018","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ejheart.2004.05.004","article-title":"The hemodynamic and neurohormonal effects of low dose tezosentan (an endothelin A\/B receptor antagonist) in patients with acute heart failure","volume":"6","author":"Cotter","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"2026020203555857000_ejhf2005-04-002-bib-0019","first-page":"677","article-title":"Rationale and design of the Canadian Positive Airway Pressure Trial for congestive heart failure patients with central sleep apnoea: CANPAP","volume":"17","author":"Bradley","year":"2001","journal-title":"Can J Cardiol"},{"key":"2026020203555857000_ejhf2005-04-002-bib-0020","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.cardfail.2004.10.001","article-title":"Treating heart failure with enhanced external counterpulsation (EECP): design of the prospective evaluation of EECP in heart failure (PEECH) trial","volume":"11","author":"Feldman","year":"2005","journal-title":"J Card Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.ejheart.2005.04.002","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/7\/5\/931\/66637711\/eurjhf_7_5_931.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/7\/5\/931\/66637711\/eurjhf_7_5_931.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:56:06Z","timestamp":1770022566000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/7\/5\/931\/8445059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,1]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2005,8,7]]},"published-print":{"date-parts":[[2005,8,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ejheart.2005.04.002","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,8]]},"published":{"date-parts":[[2005,8,1]]}}}